Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Busine... (ternative pathway which Taligen's founde...)

Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

Date:12/1/2008

ternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver under Michael Holers, M.D., which closely collaborates with an international complement biology research community. For more information, visit HYPERLINK "http://www.taligentherapeutics.com/"www.taligentherapeutics.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to development of the Company's product candidates and potential advantages of the Company's technology and product candidates. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release.

    Media Contacts:

    Robert Flamm, Ph.D. or David Schull
    Russo Partners
    (212) 845-4226
    robert.flamm@russopartnersllc.com
    david.schull@russopartnersllc.com

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Precision Therapeutics Secures $43 Million in Venture Capital Funding
2. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
3. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
4. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
5. Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
6. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
7. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
8. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
9. Cornerstone Therapeutics Announces New Board of Directors
10. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
11. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics

Post Your Comments:

(Date:11/6/2009)...ITE PLAINS, N.Y., Nov. 6 The L... participating in Gap Inc.,s Give & Get progra...ng and summer, garnered more than $1 million to su...ent education and support services. ,, During t...th, Gap Inc. will issue downloadable 30% discoun...

(Date:11/6/2009)...SHINGTON, Nov. 6 The U....e of Representatives November 6, as House members ...ed to abortion and the health care reform bill. ,...ndments to the bill, the bishops called for "a fai...ndment to keep in place current federal law on abo...

(Date:11/6/2009)...gton, VA)--Three leading scientific organizations ...ued a letter to President Obama today expressing t...ance concerning the use of personal protective equ...pected or confirmed cases of 2009 H1N1 influenza. ...ca (SHEA), the Infectious Diseases Society of Amer...

(Date:11/6/2009)...rm limitations seem to wane as years go by, resear...News) -- New research suggests that people with mu...rs of developing the disease are more likely to su...n others with the condition. , The findings, pu...th the disease who relapse within five years of de...

(Date:11/6/2009)... WAVonline - the Value-Added Dist...aveRider® Product Lines , ...lue-added distributor of wireless, security, RFID,...unced that it has partnered with Vecima Networks I...porting broadband access to cable, wireless and te...

Breaking Medicine News(10 mins):Health News:Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer 2 Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 2 Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 3 Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 4 Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 5 Health News:Prevention experts urge modification to 2009 H1N1 guidance for health care workers 2 Health News:Early Relapse of MS May Mean Fewer Issues Later 2 Health News:WAV Distribution Partners with Vecima Networks Inc. 2 Health News:WAV Distribution Partners with Vecima Networks Inc. 3

[1] Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer [0] Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable [0] Prevention experts urge modification to 2009 H1N1 guidance for health care workers [1] Early Relapse of MS May Mean Fewer Issues Later [0] WAV Distribution Partners with Vecima Networks Inc.

...Physicians and patients,of community-based medical...nhanced partnership between Physicians Practice an...o help more than 7,000 physicians in Brooklyn,and ...3LOGO ) Under this partnership, Physicians Practi...

...LEASE , PCBs may threaten killer whale populatio...ology , , Orcas or killer whales may continue to ...inated biphenyls (PCBs) for the next 30 60 years,... for better standards to protect these rare marine...

... studies go forward despite promise , , MO...n one in eight phase II cancer clinical trials wit...ase III stage that,s needed to bring a new therapy...traints, a phase III trial was unlikely. , Accord...

...Longstanding Tradition of Innovation in Sim...er, SILVER SPRING, Md. and CAMBRIDGE, Mass., Sept...al Simulation (CMS) today,announced that they are ...lling their SimCenter(TM)/SimCube(TM) solution,in ...

...r Low-power Operation and Protect Valuable Int... Systems, MOUNTAIN VIEW, Calif., Sept. 10 Demons...icient programmable technologies,Actel Corporation...tel,s flash-based ProASIC3 field-programmable gate...

...joy Medical,Group is pleased to announce that Mahe...edicine and rehabilitation practice which is based...dical director of Rush Oak Park Hospital,s,Rehabil...needs of rehabilitation patients. Dr. Ramachandran...

Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors American Chemical Society's Weekly Presspac -- Sept. 5, 2007 Study Questions Dead-End Cancer Clinical Trials B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications Dr. Mahesh Ramachandran Joins Marianjoy Medical Group

(Date:11/6/2009)..., SAN DIEGO, Nov. 6 A...nology company focused on the development of small...cancer and human immunodeficiency virus (HIV), tod...esults for the third quarter and nine months ended...wscom.com/cgi-bin/prnh/20091104/ARDEALOGO ) ,, ...

(Date:11/6/2009)..., ATLANTA, Nov. 6 Ge...ax" or "the Company"), an Atlanta-based, biopharma...eases caused by HIV-1 (Human Immunodeficiency Viru...s third quarter 2009 financial results and provide...D., President and Chief Executive Officer commente...

(Date:11/6/2009)..., PARIS, November 6 , ...Agent Linezolid for the,Treatment of Multi-Resista... Novexel, a speciality pharmaceutical company f...ntibiotics designed to overcome the significant gl...day that its most advanced oral,antibacterial NXL1...

[0] Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results [0] GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update [0] Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

...Feb. 21 Flawed policies and,bad decisions at the ...of,clinical trials which now take an average of on...l. This has delayed and even prevented the,availab...ng in increased,death and suffering for patients a...t in the United States., It,s time to reform the ...

...Tolerability at Higher Doses in Dose Escalation, ...: BNVI ) today announced that the higher doses of...01 were well tolerated. As a result, the,company w...e study longer,than previously communicated., "We...earlier, and then,transition to the full Phase 2 c...

Other Medicine Technology:Cancer Cure Coalition Proposes Major Changes at the FDA 2 Cancer Cure Coalition Proposes Major Changes at the FDA 3 Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial 2 Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial 3

Cancer Cure Coalition Proposes Major Changes at the FDA Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial

Foraminotomy Kerrison Rongeurs

Bone Rongeur

Love-Kerrison Rongeurs

Double Action Rongeurs

Medicine Products:

Foraminotomy Kerrison Rongeurs Bone Rongeur Love-Kerrison Rongeurs Double Action Rongeurs

Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Busine...(ternative pathway which Taligen's founde...),Health